Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Hypercholesterolemia - Pipeline Review, H2 2017 - Research and Markets

Research and Markets
Posted on: 23 Nov 17

The "Hypercholesterolemia - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.

Hypercholesterolemia - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Hypercholesterolemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypercholesterolemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypercholesterolemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, Preclinical, Discovery and Unknown stages are 1, 9, 13, 3, 1, 20, 9 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 7 and 2 molecules, respectively.

Hypercholesterolemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Hypercholesterolemia - Overview
  3. Hypercholesterolemia - Therapeutics Development
  4. Hypercholesterolemia - Therapeutics Assessment
  5. Hypercholesterolemia - Companies Involved in Therapeutics Development
  6. Hypercholesterolemia - Drug Profiles
  7. Hypercholesterolemia - Dormant Projects
  8. Hypercholesterolemia - Discontinued Products
  9. Hypercholesterolemia - Product Development Milestones
  10. Appendix

Companies Mentioned

  • AFFiRiS AG
  • Akcea Therapeutics Inc
  • ARMO Biosciences Inc
  • AstraZeneca Plc
  • BioLingus AG
  • Catabasis Pharmaceuticals Inc
  • Chong Kun Dang Pharmaceutical Corp
  • CymaBay Therapeutics Inc
  • Daewon Pharm Co Ltd
  • Daewoong Co Ltd
  • Dicerna Pharmaceuticals Inc
  • Dybly AG
  • Esperion Therapeutics Inc
  • Gemphire Therapeutics Inc
  • Golden Biotechnology Corp
  • Hanmi Pharmaceuticals Co Ltd
  • Immune Response BioPharma Inc
  • Kadmon Corp LLC
  • Kyorin Pharmaceutical Co Ltd
  • Leading BioSciences Inc
  • LipimetiX Development Inc
  • Lotus Pharmaceutical Co Ltd
  • Madrigal Pharmaceuticals Inc.
  • Medlab Clinical Ltd
  • Nanoform Cardiovascular Therapeutics Ltd
  • Noxopharm Ltd
  • Pfizer Inc
  • Progenra Inc
  • Regeneron Pharmaceuticals Inc
  • RegenxBio Inc
  • Serometrix LLC
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
  • The Medicines Company
  • Viking Therapeutics Inc

For more information about this report visit

View source version on

Business Wire

Last updated on: 23/11/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.